ALK and non-small cell lung carcinoma: Alectinib has been previously reported to demonstrate significant prolongation in PFS in patients with untreated ALK‐positive NSCLC, and several crizotinib‐resistant ALK rearrangements could be inhibited by alectinib.7, 8